Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration

L. E.M. Wisse, S. R. Das, C. Davatzikos, B. C. Dickerson, S. X. Xie, P. A. Yushkevich, D. A. Wolk, for the, Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticle

Abstract

Introduction: Suspected non-Alzheimer's pathophysiology (SNAP) is a biomarker driven designation that represents a heterogeneous group in terms of etiology and prognosis. SNAP has only been identified by cross-sectional neurodegeneration measures, whereas longitudinal measures might better reflect “active” neurodegeneration and might be more tightly linked to prognosis. We compare neurodegeneration defined by cross-sectional ‘hippocampal volume’ only (SNAP/L−) versus both cross-sectional and longitudinal ‘hippocampal atrophy rate’ (SNAP/L+) and investigate how these definitions impact prevalence and the clinical and biomarker profile of SNAP in Mild Cognitive Impairment (MCI). Methods: 276 MCI patients from ADNI-GO/2 were designated amyloid “positive” (A+) or “negative” (A−) based on their florbetapir scan and neurodegeneration ‘positive’ or ‘negative’ based on cross-sectional hippocampal volume and longitudinal hippocampal atrophy rate. Results: 74.1% of all SNAP participants defined by the cross-sectional definition of neurodegeneration also met the longitudinal definition of neurodegeneration, whereas 25.9% did not. SNAP/L+ displayed larger white matter hyperintensity volume, a higher conversion rate to dementia over 5 years and a steeper decline on cognitive tasks compared to SNAP/L− and the A- CN group. SNAP/L− had more abnormal values on neuroimaging markers and worse performance on cognitive tasks than the A- CN group, but did not show a difference in dementia conversion rate or longitudinal cognition. Discussion: Using a longitudinal definition of neurodegeneration in addition to a cross-sectional one identifies SNAP participants with significant cognitive decline and a worse clinical prognosis for which cerebrovascular disease may be an important driver.

Original languageEnglish (US)
Pages (from-to)407-412
Number of pages6
JournalNeuroImage: Clinical
Volume18
DOIs
StatePublished - Jan 1 2018

Fingerprint

Atrophy
Dementia
Biomarkers
Cerebrovascular Disorders
Amyloid
Neuroimaging
Cognition
Cognitive Dysfunction
White Matter
florbetapir

Keywords

  • Cross-sectional
  • Longitudinal
  • Mild cognitive impairment
  • Neurodegeneration
  • Suspected non-AD pathology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Wisse, L. E. M., Das, S. R., Davatzikos, C., Dickerson, B. C., Xie, S. X., Yushkevich, P. A., ... Alzheimer's Disease Neuroimaging Initiative (2018). Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration. NeuroImage: Clinical, 18, 407-412. https://doi.org/10.1016/j.nicl.2018.02.008

Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration. / Wisse, L. E.M.; Das, S. R.; Davatzikos, C.; Dickerson, B. C.; Xie, S. X.; Yushkevich, P. A.; Wolk, D. A.; for the; Alzheimer's Disease Neuroimaging Initiative.

In: NeuroImage: Clinical, Vol. 18, 01.01.2018, p. 407-412.

Research output: Contribution to journalArticle

Wisse, LEM, Das, SR, Davatzikos, C, Dickerson, BC, Xie, SX, Yushkevich, PA, Wolk, DA, for the & Alzheimer's Disease Neuroimaging Initiative 2018, 'Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration', NeuroImage: Clinical, vol. 18, pp. 407-412. https://doi.org/10.1016/j.nicl.2018.02.008
Wisse LEM, Das SR, Davatzikos C, Dickerson BC, Xie SX, Yushkevich PA et al. Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration. NeuroImage: Clinical. 2018 Jan 1;18:407-412. https://doi.org/10.1016/j.nicl.2018.02.008
Wisse, L. E.M. ; Das, S. R. ; Davatzikos, C. ; Dickerson, B. C. ; Xie, S. X. ; Yushkevich, P. A. ; Wolk, D. A. ; for the ; Alzheimer's Disease Neuroimaging Initiative. / Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration. In: NeuroImage: Clinical. 2018 ; Vol. 18. pp. 407-412.
@article{b9a89d8e8f5e4a6baf4e1d70405d4ca6,
title = "Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration",
abstract = "Introduction: Suspected non-Alzheimer's pathophysiology (SNAP) is a biomarker driven designation that represents a heterogeneous group in terms of etiology and prognosis. SNAP has only been identified by cross-sectional neurodegeneration measures, whereas longitudinal measures might better reflect “active” neurodegeneration and might be more tightly linked to prognosis. We compare neurodegeneration defined by cross-sectional ‘hippocampal volume’ only (SNAP/L−) versus both cross-sectional and longitudinal ‘hippocampal atrophy rate’ (SNAP/L+) and investigate how these definitions impact prevalence and the clinical and biomarker profile of SNAP in Mild Cognitive Impairment (MCI). Methods: 276 MCI patients from ADNI-GO/2 were designated amyloid “positive” (A+) or “negative” (A−) based on their florbetapir scan and neurodegeneration ‘positive’ or ‘negative’ based on cross-sectional hippocampal volume and longitudinal hippocampal atrophy rate. Results: 74.1{\%} of all SNAP participants defined by the cross-sectional definition of neurodegeneration also met the longitudinal definition of neurodegeneration, whereas 25.9{\%} did not. SNAP/L+ displayed larger white matter hyperintensity volume, a higher conversion rate to dementia over 5 years and a steeper decline on cognitive tasks compared to SNAP/L− and the A- CN group. SNAP/L− had more abnormal values on neuroimaging markers and worse performance on cognitive tasks than the A- CN group, but did not show a difference in dementia conversion rate or longitudinal cognition. Discussion: Using a longitudinal definition of neurodegeneration in addition to a cross-sectional one identifies SNAP participants with significant cognitive decline and a worse clinical prognosis for which cerebrovascular disease may be an important driver.",
keywords = "Cross-sectional, Longitudinal, Mild cognitive impairment, Neurodegeneration, Suspected non-AD pathology",
author = "Wisse, {L. E.M.} and Das, {S. R.} and C. Davatzikos and Dickerson, {B. C.} and Xie, {S. X.} and Yushkevich, {P. A.} and Wolk, {D. A.} and {for the} and {Alzheimer's Disease Neuroimaging Initiative}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.nicl.2018.02.008",
language = "English (US)",
volume = "18",
pages = "407--412",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration

AU - Wisse, L. E.M.

AU - Das, S. R.

AU - Davatzikos, C.

AU - Dickerson, B. C.

AU - Xie, S. X.

AU - Yushkevich, P. A.

AU - Wolk, D. A.

AU - for the

AU - Alzheimer's Disease Neuroimaging Initiative

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Suspected non-Alzheimer's pathophysiology (SNAP) is a biomarker driven designation that represents a heterogeneous group in terms of etiology and prognosis. SNAP has only been identified by cross-sectional neurodegeneration measures, whereas longitudinal measures might better reflect “active” neurodegeneration and might be more tightly linked to prognosis. We compare neurodegeneration defined by cross-sectional ‘hippocampal volume’ only (SNAP/L−) versus both cross-sectional and longitudinal ‘hippocampal atrophy rate’ (SNAP/L+) and investigate how these definitions impact prevalence and the clinical and biomarker profile of SNAP in Mild Cognitive Impairment (MCI). Methods: 276 MCI patients from ADNI-GO/2 were designated amyloid “positive” (A+) or “negative” (A−) based on their florbetapir scan and neurodegeneration ‘positive’ or ‘negative’ based on cross-sectional hippocampal volume and longitudinal hippocampal atrophy rate. Results: 74.1% of all SNAP participants defined by the cross-sectional definition of neurodegeneration also met the longitudinal definition of neurodegeneration, whereas 25.9% did not. SNAP/L+ displayed larger white matter hyperintensity volume, a higher conversion rate to dementia over 5 years and a steeper decline on cognitive tasks compared to SNAP/L− and the A- CN group. SNAP/L− had more abnormal values on neuroimaging markers and worse performance on cognitive tasks than the A- CN group, but did not show a difference in dementia conversion rate or longitudinal cognition. Discussion: Using a longitudinal definition of neurodegeneration in addition to a cross-sectional one identifies SNAP participants with significant cognitive decline and a worse clinical prognosis for which cerebrovascular disease may be an important driver.

AB - Introduction: Suspected non-Alzheimer's pathophysiology (SNAP) is a biomarker driven designation that represents a heterogeneous group in terms of etiology and prognosis. SNAP has only been identified by cross-sectional neurodegeneration measures, whereas longitudinal measures might better reflect “active” neurodegeneration and might be more tightly linked to prognosis. We compare neurodegeneration defined by cross-sectional ‘hippocampal volume’ only (SNAP/L−) versus both cross-sectional and longitudinal ‘hippocampal atrophy rate’ (SNAP/L+) and investigate how these definitions impact prevalence and the clinical and biomarker profile of SNAP in Mild Cognitive Impairment (MCI). Methods: 276 MCI patients from ADNI-GO/2 were designated amyloid “positive” (A+) or “negative” (A−) based on their florbetapir scan and neurodegeneration ‘positive’ or ‘negative’ based on cross-sectional hippocampal volume and longitudinal hippocampal atrophy rate. Results: 74.1% of all SNAP participants defined by the cross-sectional definition of neurodegeneration also met the longitudinal definition of neurodegeneration, whereas 25.9% did not. SNAP/L+ displayed larger white matter hyperintensity volume, a higher conversion rate to dementia over 5 years and a steeper decline on cognitive tasks compared to SNAP/L− and the A- CN group. SNAP/L− had more abnormal values on neuroimaging markers and worse performance on cognitive tasks than the A- CN group, but did not show a difference in dementia conversion rate or longitudinal cognition. Discussion: Using a longitudinal definition of neurodegeneration in addition to a cross-sectional one identifies SNAP participants with significant cognitive decline and a worse clinical prognosis for which cerebrovascular disease may be an important driver.

KW - Cross-sectional

KW - Longitudinal

KW - Mild cognitive impairment

KW - Neurodegeneration

KW - Suspected non-AD pathology

UR - http://www.scopus.com/inward/record.url?scp=85041746990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041746990&partnerID=8YFLogxK

U2 - 10.1016/j.nicl.2018.02.008

DO - 10.1016/j.nicl.2018.02.008

M3 - Article

VL - 18

SP - 407

EP - 412

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

ER -